Zeaxanthin

Strong evidence from AREDS2 for slowing macular degeneration progression when combined with lutein. Standard of care for eye health.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

AREDS2 trial demonstrated that lutein/zeaxanthin (10 mg/2 mg) was as effective as beta-carotene for AMD progression and safer (no lung cancer risk in smokers). Macular pigment optical density is a validated biomarker.

• Filters harmful blue light in the macula
• Reduces AMD progression (AREDS2)
• Supports macular pigment optical density

2 mg daily (AREDS2 dose) combined with 10 mg lutein. Some supplements provide up to 4 mg.

• Carotenemia at very high doses (harmless)
• Generally very well tolerated

Generally very safe. Carotenemia (yellow skin) at high doses is harmless and reversible.

Almost always studied in combination with lutein. Benefits are primarily for eye health, not systemic antioxidant use.

• Longevity50